Yatharth Hospital & Trauma Care Services Ltd

Yatharth Hospital's stock has surged over 90% since its IPO last August, prompting Phillip Capital to issue a 'buy' recommendation with a target price of ₹ 827. The company is expected to achieve strong revenue growth through bed capacity expansion and improved occupancy rates.

The country's nodal organ transplant agency has sought a report from the UP government and directed it to take stringent action against the culprits after a kidney transplant racket came to light in the Delhi-NCR region recently. Investigation in the racket continues.

After a 61 percent jump in the stock from its IPO price (listed in August 2023), brokerage house SMIFS sees another 36 percent rise in healthcare company Yatharth Hospitals & Trauma Care Services in the next 12 months.

Q3 results 2024: Yatharth Hospital shares surge after announcing Q3FY24 results with a 39% YoY rise in PAT and 21% surge in operational revenue

Yatharth Hospital & Trauma Care Services saw its shares surge 10.75% in response to its strong performance in Q2FY24. The company reported a 34% YoY improvement in revenues, a 36% YoY rise in EBITDA, and a 70% improvement in net profit.

The tax department has seized some documents and is questioning some of the key managerial persons of the group, said the report citing the sources

The latest entrant to the Street, Yatharth Hospital reported a net profit of 19 crore, a growth of 73% year-on-year (YoY) for the quarter ended June.

Yatharth Hospital share price opened at ₹ 304 on BSE and went on to hit intraday high of ₹ 342.70 apiece levels, logging over 10 per cent gain against the upper price band of the IPO